ポイント・オブ・ケア（POC）診断市場規模、シェア、動向、2031年までの世界予測

ポイント・オブ・ケア（POC）診断市場は、2026年の206億3,000万米ドルから、年平均成長率（CAGR）8.8%で成長し、2031年には314億6,000万米ドルに達するとMarketsandMarketsでは予測しています。

継続的な技術の進歩と、迅速かつ正確で分散型の検査に対する需要の高まりが、ポイント・オブ・ケア（POC）診断市場の成長を牽引しています。生化学技術は、血糖モニタリング、血液ガス・電解質分析、コレステロール検査など、病院、臨床検査室、救急部門、診療所における日常的な診断用途で広く利用されていることから、最大の市場シェアを占めています。その幅広い臨床的有用性、費用対効果、そして迅速な結果提供能力により、生化学技術は大量のPOC検査を行う上で好まれる技術となっています。一方、感染症の検出、薬剤耐性検査、アウトブレイク（集団感染）への備えを目的とした迅速PCRプラットフォームの導入拡大に伴い、分子診断分野が最も急速に成長すると予測されています。免疫測定法、分子診断プラットフォーム、マイクロ流体技術、マルチプレックス検査、ポータブル分析装置における絶え間ない技術革新は、診断精度の向上、検査所要時間の短縮、そして従来の検査室の枠を超えた検査の拡大をもたらしています。こうした進歩により、病院、外来診療施設、小売店併設型クリニック、薬局、在宅医療の現場における次世代POC診断技術の導入が加速し、高度な診断ソリューションに対する持続的な世界需要が創出されています。

調査対象範囲

本レポートは、ポイント・オブ・ケア（POC）診断市場を評価し、製品、エンドユーザー、地域などの各セグメントに基づいて、市場規模および将来の成長性を推定しています。また、主要企業の競合分析に加え、各社の企業概要、製品ラインナップ、最近の動向、主要な市場戦略についても取り上げています。

本レポートを購入するメリット

本レポートは、ポイント・オブ・ケア（POC）診断市場における市場リーダーや新規参入企業に対し、市場全体および各セグメントの推定収益データを提供します。ステークホルダーは、本レポートを通じて競争環境を把握し、自社の事業の立ち位置を最適化したり、効果的な市場参入戦略を策定したりするための知見を得ることができます。さらに、市場の力学を理解し、POC診断市場に影響を与える主要な促進要因、阻害要因、課題、および成長機会に関する洞察を得ることも可能です。

本レポートでは、以下の点に関する知見を提供します。

主要な推進要因の分析（糖尿病・心血管疾患・迅速な診断を要する感染症などの慢性疾患の有病率上昇、迅速な臨床判断を可能にする分散型・患者近接型検査への需要拡大、病院・診療所・在宅ケア現場における携帯型かつ使いやすい診断機器の導入増加、マイクロ流体工学・バイオセンサー・AI活用診断・スマートフォン連携検査ソリューションにおける技術進歩）、阻害要因（高度なPOC診断機器および消耗品の高コスト、厳格な規制承認および品質適合要件、中央検査室での検査と比較した一部の迅速検査の精度限界、コネクテッド診断システムに伴うデータセキュリティや相互運用性への懸念）、機会（新興国市場におけるPOC検査の拡大、在宅用診断キットや自己検査ソリューションへの需要増、マルチプレックスおよび分子診断POC検査の導入拡大、デジタルヘルス・遠隔医療・AI搭載診断プラットフォームへの投資増加）、および課題（医療リソースの限られた地域における医療インフラや専門人材の不足、償還および価格設定に関する圧力、診断用試薬・消耗品のサプライチェーン制約、POC診断データと電子カルテシステムとの標準化および統合）

• 製品の改良・革新：世界のPOC診断市場における製品投入および今後のトレンドに関する詳細情報。
• 市場の発展：製品、検体、購入形態、技術、エンドユーザー、地域別の有望な成長市場に関する深い知見と分析。
• 市場の多角化：世界のPOC診断市場における新製品投入、市場拡大、最新の技術進歩、投資動向に関する包括的な情報。
• 競合状況の評価：世界のPOC診断市場における主要企業の市場シェア、成長戦略、製品・サービス内容、および事業能力に関する詳細な評価。

Report Description

The Point of Care Diagnostics market is projected to reach USD 31.46 billion by 2031 from USD 20.63 billion in 2026, growing at a CAGR of 8.8%.

Continuous technological advancements and the growing demand for rapid, accurate, and decentralized testing are driving growth in the point-of-care diagnostics market. Biochemistry technology accounts for the largest market share due to its widespread use in blood glucose monitoring, blood gas and electrolyte analysis, cholesterol testing, and other routine diagnostic applications across hospitals, clinical laboratories, emergency departments, and physician offices. Its broad clinical utility, cost-effectiveness, and ability to deliver rapid results make it the preferred technology for high-volume point-of-care testing. Meanwhile, molecular diagnostics is projected to grow the fastest, owing to the increasing adoption of rapid PCR-based platforms for infectious disease detection, antimicrobial resistance testing, and outbreak preparedness. Continuous innovations in immunoassays, molecular platforms, microfluidics, multiplex testing, and portable analyzers are improving diagnostic accuracy, reducing turnaround time, and expanding testing beyond traditional laboratories. These advancements are accelerating the adoption of next-generation point-of-care diagnostic technologies across hospitals, ambulatory care facilities, retail clinics, pharmacies, and home healthcare settings, thereby creating sustained global demand for advanced diagnostic solutions.

Based on product: Infectious disease testing products are projected to register the highest growth during the forecast period. The segment’s dominance is driven by the increasing burden of infectious diseases, the growing demand for rapid, accurate near-patient diagnosis, and the need for timely clinical decision-making to support effective treatment and infection control. The growing adoption of point-of-care testing across hospitals, emergency departments, physicians’ offices, retail clinics, pharmacies, and home healthcare settings, coupled with expanding government initiatives for infectious disease surveillance and decentralized healthcare delivery, continues to strengthen the market position of infectious disease testing products.

Based on end user: Clinical laboratories account for the largest share of the point-of-care diagnostics market due to their central role in delivering rapid and accurate diagnostic testing for both acute and chronic diseases. These facilities routinely perform point-of-care testing for infectious diseases, diabetes, cardiovascular disorders, coagulation monitoring, and clinical chemistry, supporting timely diagnosis and treatment decisions. Their extensive testing capabilities, skilled laboratory personnel, established quality management systems, and seamless integration with hospital workflows continue to drive demand for point-of-care diagnostic solutions. Furthermore, increasing test volumes, the growing emphasis on faster turnaround times, and the expanding adoption of decentralized testing within laboratory networks reinforce the dominance of clinical laboratories in the global point-of-care diagnostics market.

North America accounts for the largest share of the point-of-care diagnostics market due to its advanced healthcare infrastructure, strong reimbursement framework, and widespread adoption of decentralized diagnostic testing. The region has an extensive network of hospitals, clinical laboratories, physicians’ offices, urgent care centers, retail clinics, and pharmacies that routinely use point-of-care diagnostics to rapidly detect and manage infectious diseases, diabetes, cardiovascular disorders, and respiratory conditions. High healthcare expenditure, a strong presence of leading diagnostic manufacturers, and favorable regulatory support have accelerated the adoption of point-of-care testing across the U.S. and Canada. Furthermore, increasing emphasis on early diagnosis, improved patient outcomes, and reducing healthcare costs through near-patient testing continues to reinforce North America’s leadership in the global point-of-care diagnostics market.

A breakdown of the primary respondents (supply-side) for the POC diagnostics s market referred to in this report is provided below:

• By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30%
• By Designation: C-level: 55%, Director Level: 27%, and Others: 18%
• By Region: North America: 43%, Europe: 28%, Asia Pacific: 20%, Latin America: 6%, and Middle East & Africa: 3%

Prominent players in the global point-of-care diagnostics market include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (US), bioMérieux SA (France), Werfen S.A. (Spain), Becton, Dickinson and Company (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), OraSure Technologies, Inc. (US), EKE Diagnostics (China), Trinity Biotech plc (Ireland), Grifols S.A. (Spain), Nova Biomedical Corporation (US), Sekisui Diagnostics, LLC (US), Trividia Health, Inc. (US), Sysmex Corporation (Japan), HemoCue AB (Sweden), and Bio-Rad Laboratories, Inc. (US) among others.

Research Coverage

The report evaluates the POC diagnostics market and estimates the market size and future growth potential of this market based on various segments, including product, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will assist market leaders and new entrants in the POC diagnostics s market with data on the nearest approximations of revenue figures for the overall market and its subsegments. The report will help stakeholders understand the competitive landscape and gain insights to better position their businesses and develop effective go-to-market strategies. It also enables stakeholders to understand market dynamics and provides insights into key drivers, restraints, challenges, and growth opportunities influencing the POC diagnostics market.

This report provides insights into the following points:

Analysis of key drivers (rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and infectious diseases requiring rapid diagnosis, growing demand for decentralized and near-patient testing to enable faster clinical decision-making, increasing adoption of portable and user-friendly diagnostic devices in hospitals, clinics, and home care settings, technological advancements in microfluidics, biosensors, AI-enabled diagnostics, and smartphone-integrated testing solutions), restraints (high cost of advanced point-of-care diagnostic devices and consumables, stringent regulatory approval and quality compliance requirements, limited accuracy of certain rapid tests compared to centralized laboratory testing, data security and interoperability concerns with connected diagnostic systems), opportunities (expansion of point-of-care testing in emerging markets, increasing demand for home-based diagnostic kits and self-testing solutions, growing adoption of multiplex and molecular point-of-care diagnostics, rising investments in digital health, telemedicine, and AI-powered diagnostic platforms), and challenges (limited healthcare infrastructure and trained personnel in low-resource settings, reimbursement and pricing pressures, supply chain constraints for diagnostic reagents and consumables, standardization and integration of point-of-care diagnostic data with electronic health record systems)

• Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global POC diagnostics market.
• Market Development: Thorough knowledge and analysis of the profitable rising markets by product, sample, mode of purchase, technology, end user, and region.
• Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global POC diagnostics market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global POC diagnostics market.

Table of Contents

1 INTRODUCTION 48
1.1 STUDY OBJECTIVES 48
1.2 MARKET DEFINITION 48
1.3 STUDY SCOPE 49
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 49
1.3.2 INCLUSIONS AND EXCLUSIONS 50
1.3.3 YEARS CONSIDERED 51
1.3.4 CURRENCY CONSIDERED 52
1.4 STAKEHOLDERS 52
1.5 SUMMARY OF CHANGES 52
2 EXECUTIVE SUMMARY 54
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 54
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 55
2.3 DISRUPTIVE TRENDS SHAPING MARKET 56
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 57
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 58
3 PREMIUM INSIGHTS 60
3.1 POC DIAGNOSTICS MARKET OVERVIEW 60
3.2 POC DIAGNOSTICS MARKET, BY PRODUCT, 2026 VS. 2031 61
3.3 POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2026 VS. 2031 61
3.4 POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031 62
3.5 POC DIAGNOSTICS MARKET, BY SAMPLE, 2026 VS. 2031 62
3.6 POC DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031 63
3.7 POC DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63
4 MARKET OVERVIEW 64
4.1 INTRODUCTION 64
4.2 MARKET DYNAMICS 64
4.2.1 DRIVERS 65
4.2.1.1 Growing incidence of infectious diseases 65
4.2.1.2 Increasing prevalence of chronic diseases 67
4.2.1.3 Favorable government initiatives for POC testing 68
4.2.1.4 Rising number of waived tests 69
4.2.2 RESTRAINTS 70
4.2.2.1 Pricing pressure on manufacturers 70
4.2.2.2 Stringent regulatory approval process for product commercialization 71
4.2.3 OPPORTUNITIES 71
4.2.3.1 Increasing growth potential in emerging markets 71
4.2.3.2 Rising inclination toward decentralized healthcare systems 72
4.2.3.3 Booming healthcare spending worldwide 72
4.2.4 CHALLENGES 73
4.2.4.1 Inadequate standardization with centralized lab methods 73
4.2.4.2 Premium pricing of novel platforms 74
4.3 UNMET NEEDS AND WHITE SPACES 74
4.3.1 UNMET NEEDS IN POC DIAGNOSTICS MARKET 74
4.3.2 WHITE SPACE OPPORTUNITIES 75
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 76
4.4.1 INTERCONNECTED MARKETS 76
4.4.2 CROSS-SECTOR OPPORTUNITIES 78
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 79
4.5.1 KEY MOVES AND STRATEGIC FOCUS 79
5 INDUSTRY TRENDS 80
5.1 PORTER’S FIVE FORCES ANALYSIS 80
5.1.1 BARGAINING POWER OF SUPPLIERS 81
5.1.2 BARGAINING POWER OF BUYERS 81
5.1.3 THREAT OF NEW ENTRANTS 81
5.1.4 THREAT OF SUBSTITUTES 81
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 81
5.2 MACROECONOMIC INDICATORS 82
5.2.1 INTRODUCTION 82
5.2.2 GDP TRENDS AND FORECAST 82
5.3 SUPPLY CHAIN ANALYSIS 85
5.4 ECOSYSTEM ANALYSIS 86
5.5 INVESTMENT AND FUNDING SCENARIO 88
5.6 PRICING ANALYSIS 89
5.6.1 AVERAGE SELLING PRICE, BY PRODUCT 89
5.6.1.1 Average selling price OF glucose monitoring test strips, by key player 90
5.6.2 AVERAGE SELLING PRICE, BY REGION 90
5.6.2.1 Average selling price of glucose monitoring test strips, by region 90
5.6.2.2 Average selling price of infectious disease testing products, by region 91
5.6.2.3 Average selling price of cardiometabolic monitoring products,
by region 92
5.7 VALUE CHAIN ANALYSIS 93
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 94
5.9 IMPACT OF US TARIFFS—POC DIAGNOSTICS MARKET 95
5.9.1 INTRODUCTION 95
5.9.2 KEY TARIFF RATES 96
5.9.3 PRICE IMPACT ANALYSIS 96
5.9.4 IMPACT ON COUNTRIES/REGIONS 97
5.9.4.1 North America 97
5.9.4.2 Europe 97
5.9.4.3 Asia Pacific 97
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 98
6.1 KEY EMERGING TECHNOLOGIES 98
6.1.1 IMMUNOASSAYS 98
6.2 COMPLEMENTARY TECHNOLOGIES 98
6.2.1 MOLECULAR DIAGNOSTICS 98
6.3 ADJACENT TECHNOLOGIES 99
6.3.1 BIOCHEMICAL TECHNOLOGIES 99
6.4 TECHNOLOGY/PRODUCT ROADMAP 100
6.5 PATENT ANALYSIS 101
6.5.1 LIST OF MAJOR PATENTS 102
6.6 FUTURE APPLICATIONS 102
6.7 IMPACT OF AI/GENERATIVE AI ON POC DIAGNOSTICS MARKET 103
6.7.1 INTRODUCTION 103
6.7.2 TOP USE CASES AND MARKET POTENTIAL 104
6.7.3 KEY COMPANIES IMPLEMENTING AI 104
6.7.4 FUTURE OF AI 106
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 107
7.1 REGIONAL REGULATIONS AND COMPLIANCE 107
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107
7.1.2 INDUSTRY STANDARDS 109
7.2 SUSTAINABILITY INITIATIVES 111
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN POC DIAGNOSTICS 111
7.2.1.1 Eco-friendly Initiatives 111
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 112
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 113
8.1 DECISION-MAKING PROCESS 113
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 113
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 113
8.2.2 BUYING CRITERIA 114
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 115
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 116
8.5 MARKET PROFITABILITY 117
8.5.1 REVENUE POTENTIAL 117
8.5.2 COST DYNAMICS 117
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 118
9 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY 119
9.1 INTRODUCTION 120
9.2 BIOCHEMISTRY 120
9.2.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH 120
9.3 IMMUNOASSAYS 123
9.3.1 GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET 123
9.4 MOLECULAR DIAGNOSTICS 127
9.4.1 RT-PCR 130
9.4.1.1 Growing use of RT-PCR in proteomics and genomics to boost market 130
9.4.2 INAAT 132
9.4.2.1 Emerging new pathogens to facilitate growth 132
10 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE 135
10.1 INTRODUCTION 136
10.2 BLOOD SAMPLES 136
10.2.1 GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET 136
10.3 NASAL & OROPHARYNGEAL SWABS 140
10.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH 140
10.4 URINE SAMPLES 143
10.4.1 NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET 143
10.5 OTHER SAMPLES 146
11 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE 150
11.1 INTRODUCTION 151
11.2 PRESCRIPTION-BASED TESTING PRODUCTS 151
11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH 151
11.3 OTC TESTING PRODUCTS 155
11.3.1 GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET 155
12 POINT OF CARE DIAGNOSTICS MARKET, BY END USER 159
12.1 INTRODUCTION 160
12.2 CLINICAL LABORATORIES 160
12.2.1 GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET 160
12.3 HOME CARE SETTINGS & SELF-TESTING 163
12.3.1 INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH 163
12.4 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS 165
12.4.1 RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH 165
12.5 AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES 168
12.5.1 NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH 168
12.6 OTHER END USERS 171
13 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT 174
13.1 INTRODUCTION 175
13.2 GLUCOSE MONITORING PRODUCTS 176
13.2.1 GLUCOSE MONITORING STRIPS 178
13.2.1.1 Growing trend toward preventive healthcare to drive market 178
13.2.2 GLUCOSE MONITORING METERS 181
13.2.2.1 Growing technological advancements in glucose meters to propel market 181
13.2.3 GLUCOSE MONITORING LANCETS & LANCING DEVICES 184
13.2.3.1 Increasing tendency for home-based care and self-monitoring to aid growth 184
13.3 CARDIOMETABOLIC TESTING PRODUCTS 186
13.3.1 CARDIAC MARKER TESTING PRODUCTS 190
13.3.1.1 Growing government support for cardiovascular diseases to drive market 190
13.3.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS 192
13.3.2.1 Need to optimize hospital workflow to favor growth 192
13.3.3 HBA1C TESTING PRODUCTS 195
13.3.3.1 Increasing recommendations by government healthcare authorities to boost market 195
13.4 INFECTIOUS DISEASE TESTING PRODUCTS 197
13.4.1 RESPIRATORY INFECTION TESTING PRODUCTS 200
13.4.1.1 Influenza testing products 203
13.4.1.1.1 Need for targeted treatments to expedite growth 203
13.4.1.2 Tuberculosis testing products 206
13.4.1.2.1 Increasing demand for diagnostic products and services to contribute to growth 206
13.4.1.3 Other respiratory infection testing products 208
13.4.2 HAI TESTING PRODUCTS 211
13.4.2.1 Growing rate of surgical-site infections to boost market 211
13.4.3 TROPICAL DISEASE TESTING PRODUCTS 214
13.4.3.1 Rising incidence of malaria and dengue to support growth 214
13.4.4 STD TESTING PRODUCTS 216
13.4.4.1 HIV testing products 219
13.4.4.1.1 Growing availability and awareness of testing products to boost market 219
13.4.4.2 Hepatitis testing products 222
13.4.4.2.1 Hepatitis B testing products 224
13.4.4.2.1.1 Increasing prevalence of liver infections to favor growth 224
13.4.4.2.2 Hepatitis C testing products 227
13.4.4.2.2.1 Need to combat hepatitis among high-risk subgroup populations to aid growth 227
13.4.4.3 Syphilis testing products 229
13.4.4.3.1 Need for early and accessible diagnosis to expedite growth 229
13.4.4.4 Human papillomavirus testing products 232
13.4.4.4.1 Rising cases of cervical cancer to promote growth 232
13.4.4.5 Chlamydia trachomatis testing products 235
13.4.4.5.1 Growing adoption of advanced techniques to drive market 235
13.4.4.6 Neisseria gonorrhea testing products 238
13.4.4.6.1 Rising incidence of gonorrhea and antimicrobial resistance to augment growth 238
13.4.4.7 HSV testing products 240
13.4.4.7.1 Increasing incidence of herpes to support growth 240
13.4.5 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS 243
13.4.5.1 Rising cases among hospitalized patients to boost demand 243
13.4.6 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 245
13.5 COAGULATION MONITORING PRODUCTS 248
13.5.1 NEED FOR REGULAR MONITORING AND RISING DEMAND FOR HOME-USE KITS TO PROPEL MARKET 248
13.5.2 PT/INR TESTING PRODUCTS 251
13.5.2.1 Increasing number of atrial fibrillation cases to accelerate growth 251
13.5.3 ACT/APTT TESTING PRODUCTS 253
13.5.3.1 Rise in surgical procedures to speed up growth 253
13.6 PREGNANCY & FERTILITY TESTING PRODUCTS 255
13.6.1 PREGNANCY TESTING PRODUCTS 257
13.6.1.1 Increasing awareness about family planning to stimulate growth 257
13.6.2 FERTILITY TESTING PRODUCTS 260
13.6.2.1 Growing infertility issues to fuel market 260
13.7 TUMOR/CANCER MARKER TESTING PRODUCTS 263
13.7.1 GROWING CANCER INCIDENCE AND GOVERNMENT SUPPORT FOR CANCER MANAGEMENT AND THERAPIES DRIVE MARKET 263
13.8 URINALYSIS TESTING PRODUCTS 266
13.8.1 INCREASING DEMAND FOR RAPID POC TESTING TECHNOLOGIES TO SUPPORT MARKET GROWTH 266
13.9 CHOLESTEROL TESTING PRODUCTS 269
13.9.1 GROWING GERIATRIC POPULATION AND RISING OBESITY LEVELS TO DRIVE MARKET 269
13.10 HEMATOLOGY TESTING PRODUCTS 272
13.10.1 RAPID DIAGNOSTICS AND MONITORING SUPPORT TO PROPEL END-USER ADOPTION 272
13.11 DRUGS-OF-ABUSE TESTING PRODUCTS 275
13.11.1 GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET 275
13.12 THYROID-STIMULATING HORMONE TESTING PRODUCTS 278
13.12.1 GROWING PREVALENCE OF THYROID DISORDERS DRIVING DEMAND FOR TSH TESTING PRODUCTS 278
13.13 FECAL OCCULT TESTING PRODUCTS 280
13.13.1 GROWING INCIDENCE OF CANCER TO PROPEL THE MARKET 280
13.14 OTHER PRODUCTS 283
14 POINT OF CARE DIAGNOSTICS MARKET, BY REGION 287
14.1 INTRODUCTION 288
14.2 NORTH AMERICA 288
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 289
14.2.2 US 296
14.2.2.1 Presence of advanced healthcare infrastructure and high healthcare expenditure to aid growth 296
14.2.3 CANADA 302
14.2.3.1 Rising incidence of diabetes and infectious diseases to support growth 302
14.3 EUROPE 308
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 309
14.3.2 GERMANY 316
14.3.2.1 Increasing need for rapid and accurate diagnostic solutions to promote growth 316
14.3.3 FRANCE 322
14.3.3.1 Growing demand for accessible and convenient diagnostic tools to propel market 322
14.3.4 UK 328
14.3.4.1 Rising number of accredited clinical and hospital laboratories to sustain growth 328
14.3.5 ITALY 334
14.3.5.1 Growing burden of infectious and parasitic diseases to boost market 334
14.3.6 SPAIN 340
14.3.6.1 Rising prevalence of circulatory system diseases to contribute to growth 340
14.3.7 REST OF EUROPE 346
14.4 ASIA PACIFIC 352
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 352
14.4.2 CHINA 359
14.4.2.1 Increasing impact of diabetes on public health to amplify growth 359
14.4.3 JAPAN 365
14.4.3.1 Booming geriatric population to stimulate growth 365
14.4.4 INDIA 371
14.4.4.1 Increasing cases of chronic heart and kidney diseases to foster growth 371
14.4.5 AUSTRALIA 378
14.4.5.1 Growing research investments for next-gen POC devices to boost market 378
14.4.6 SOUTH KOREA 384
14.4.6.1 Growing focus on innovative diagnostic products to drive market 384
14.4.7 REST OF ASIA PACIFIC 390
14.5 LATIN AMERICA 395
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 396
14.5.2 BRAZIL 402
14.5.2.1 Increasing public initiatives in healthcare to encourage growth 402
14.5.3 MEXICO 408
14.5.3.1 Need for frequent testing for disease management to expedite growth 408
14.5.4 REST OF LATIN AMERICA 414
14.6 MIDDLE EAST & AFRICA 420
14.6.1 GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET 420
14.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 420
15 COMPETITIVE LANDSCAPE 426
15.1 INTRODUCTION 426
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 426
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POC DIAGNOSTICS MARKET 426
15.3 REVENUE ANALYSIS, 2023–2025 428
15.4 MARKET SHARE ANALYSIS, 2025 429
15.5 COMPANY VALUATION AND FINANCIAL METRICS 431
15.6 BRAND/PRODUCT COMPARISON 432
15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 433
15.7.1 STARS 433
15.7.2 EMERGING LEADERS 433
15.7.3 PERVASIVE PLAYERS 433
15.7.4 PARTICIPANTS 433
15.7.5 COMPANY FOOTPRINT, KEY PLAYERS, 2025 435
15.7.5.1 Company footprint 435
15.7.5.2 Region footprint 436
15.7.5.3 Mode of purchase footprint 437
15.7.5.4 Technology footprint 438
15.7.5.5 Sample footprint 439
15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 440
15.8.1 PROGRESSIVE COMPANIES 440
15.8.2 RESPONSIVE COMPANIES 440
15.8.3 DYNAMIC COMPANIES 440
15.8.4 STARTING BLOCKS 440
15.8.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 442
15.8.5.1 Detailed list of key startups/SMEs 442
15.8.5.2 Competitive benchmarking of startups/SMEs 443
15.9 COMPETITIVE SCENARIO 444
15.9.1 PRODUCT LAUNCHES AND APPROVALS 444
16 COMPANY PROFILES 445
16.1 KEY PLAYERS 445
16.1.1 ABBOTT 445
16.1.1.1 Business overview 445
16.1.1.2 Products offered 446
16.1.1.3 Recent developments 449
16.1.1.3.1 Product launches and approvals 449
16.1.1.3.2 Deals 449
16.1.1.4 MnM view 450
16.1.1.4.1 Right to win 450
16.1.1.4.2 Strategic choices 450
16.1.1.4.3 Weaknesses and competitive threats 450
16.1.2 F. HOFFMANN-LA ROCHE LTD 451
16.1.2.1 Business overview 451
16.1.2.2 Products offered 452
16.1.2.3 Recent developments 454
16.1.2.3.1 Product launches and approvals 454
16.1.2.3.2 Deals 455
16.1.2.3.3 Expansions 455
16.1.2.4 MnM view 456
16.1.2.4.1 Right to win 456
16.1.2.4.2 Strategic choices 456
16.1.2.4.3 Weaknesses and competitive threats 456
16.1.3 SIEMENS HEALTHINEERS AG 457
16.1.3.1 Business overview 457
16.1.3.2 Products offered 458
16.1.3.3 Recent developments 460
16.1.3.3.1 Product launches and approvals 460
16.1.3.3.2 Deals 460
16.1.3.3.3 Expansions 461
16.1.3.4 MnM view 462
16.1.3.4.1 Right to win 462
16.1.3.4.2 Strategic choices 462
16.1.3.4.3 Weaknesses and competitive threats 462
16.1.4 QUIDELORTHO CORPORATION 463
16.1.4.1 Business overview 463
16.1.4.2 Products offered 464
16.1.4.3 Recent developments 466
16.1.4.3.1 Product launches and approvals 466
16.1.4.3.2 Deals 467
16.1.4.3.3 Expansions 467
16.1.4.4 MnM view 467
16.1.4.4.1 Right to win 467
16.1.4.4.2 Strategic choices 468
16.1.4.4.3 Weaknesses and competitive threats 468
16.1.5 DANAHER 469
16.1.5.1 Business overview 469
16.1.5.2 Products offered 470
16.1.5.3 Recent developments 472
16.1.5.3.1 Product launches and approvals 472
16.1.5.3.2 Deals 472
16.1.5.3.3 Expansions 473
16.1.5.4 MnM view 473
16.1.5.4.1 Right to win 473
16.1.5.4.2 Strategic choices 473
16.1.5.4.3 Weaknesses and competitive threats 473
16.1.6 WERFEN 474
16.1.6.1 Business overview 474
16.1.6.2 Products offered 475
16.1.6.3 Recent developments 476
16.1.6.3.1 Product launches and approvals 476
16.1.6.3.2 Deals 476
16.1.6.3.3 Expansions 477
16.1.6.4 MnM view 477
16.1.6.4.1 Right to win 477
16.1.6.4.2 Strategic choices 477
16.1.6.4.3 Weaknesses and competitive threats 477
16.1.7 BD 478
16.1.7.1 Business overview 478
16.1.7.2 Products offered 479
16.1.7.3 Recent developments 480
16.1.7.3.1 Product launches and approvals 480
16.1.7.3.2 Deals 480
16.1.7.3.3 Expansions 481
16.1.8 THERMO FISHER SCIENTIFIC INC. 482
16.1.8.1 Business overview 482
16.1.8.2 Products offered 484
16.1.8.3 Recent developments 484
16.1.8.3.1 Deals 484
16.1.9 BIOMÉRIEUX 485
16.1.9.1 Business overview 485
16.1.9.2 Products offered 486
16.1.9.3 Recent developments 487
16.1.9.3.1 Product launches and approvals 487
16.1.9.3.2 Deals 488
16.1.10 EKF DIAGNOSTICS HOLDINGS PLC 489
16.1.10.1 Business overview 489
16.1.10.2 Products offered 490
16.1.10.3 Recent developments 491
16.1.10.3.1 Product launches and approvals 491
16.1.10.3.2 Expansions 491
16.1.10.3.3 Other developments 492
16.1.11 TRINITY BIOTECH 493
16.1.11.1 Business overview 493
16.1.11.2 Products offered 494
16.1.11.3 Recent developments 495
16.1.11.3.1 Product launches and approvals 495
16.1.11.3.2 Deals 495
16.1.12 ORASURE TECHNOLOGIES, INC. 496
16.1.12.1 Business overview 496
16.1.12.2 Products offered 497
16.1.12.3 Recent developments 498
16.1.12.3.1 Product launches and approvals 498
16.1.12.3.2 Deals 499
16.1.13 GRIFOLS S.A. 500
16.1.13.1 Business overview 500
16.1.13.2 Products offered 501
16.1.13.3 Recent developments 502
16.1.13.3.1 Product launches and approvals 502
16.1.14 QIAGEN 503
16.1.14.1 Business overview 503
16.1.14.2 Products offered 504
16.1.14.3 Recent developments 505
16.1.14.3.1 Product launches and approvals 505
16.1.14.3.2 Deals 506
16.1.14.3.3 Expansions 506
16.2 OTHER PLAYERS 507
16.2.1 NOVA BIOMEDICAL 507
16.2.1.1 Business overview 507
16.2.1.2 Products offered 507
16.2.1.3 Recent developments 508
16.2.1.3.1 Product launches and approvals 508
16.2.1.3.2 Deals 509
16.2.2 SEKISUI DIAGNOSTICS 510
16.2.2.1 Business overview 510
16.2.2.2 Products offered 510
16.2.2.3 Recent developments 511
16.2.2.3.1 Product launches and approvals 511
16.2.3 SEKISUI DIAGNOSTICS 512
16.2.3.1 Business overview 512
16.2.3.2 Products offered 512
16.2.3.3 Recent developments 513
16.2.3.3.1 Product launches and approvals 513
16.2.4 LIFESCAN IP HOLDINGS, LLC 514
16.2.5 PTS DIAGNOSTICS 515
16.2.6 EUROLYSER DIAGNOSTICA GMBH 516
16.2.7 RESPONSE BIOMEDICAL 517
16.2.8 ALFA SCIENTIFIC DESIGNS, INC. 518
16.2.9 BTNX INC. 519
16.2.10 ASCENSIA DIABETES CARE HOLDINGS AG 520
16.2.11 FLUXERGY 521
16.2.12 PRECISION BIOSENSOR, INC. 522
16.2.13 ACON LABORATORIES, INC. 523
16.2.14 MENARINI DIAGNOSTICS S.R.L 524
16.2.15 MANKIND PHARMA 525
17 RESEARCH METHODOLOGY 526
17.1 RESEARCH DATA 526
17.2 RESEARCH APPROACH 526
17.2.1 SECONDARY RESEARCH 527
17.2.1.1 Key data from secondary sources 527
17.2.2 PRIMARY DATA 528
17.2.2.1 Primary sources 529
17.2.2.2 Key data from primary sources 530
17.2.2.3 Key industry insights 531
17.3 MARKET SIZE ESTIMATION 532
17.3.1 BOTTOM-UP APPROACH 533
17.3.1.1 Approach 1: Company revenue estimation approach 533
17.3.1.2 Approach 2: Presentations of companies and primary interviews 534
17.3.1.3 Growth forecast 534
17.3.2 TOP-DOWN APPROACH 535
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION 536
17.5 MARKET SHARE ANALYSIS 537
17.6 RESEARCH ASSUMPTIONS 537
17.6.1 PARAMETRIC ASSUMPTIONS 537
17.6.2 GROWTH RATE ASSUMPTIONS 538
17.7 RESEARCH LIMITATIONS 538
17.8 RISK ASSESSMENT 538
18 APPENDIX 539
18.1 DISCUSSION GUIDE 539
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 544
18.3 CUSTOMIZATION OPTIONS 546
18.4 RELATED REPORTS 546
18.5 AUTHOR DETAILS 547

LIST OF TABLES

TABLE 1 PROJECTED INCREASE OF CANCER PATIENTS, BY REGION,
2025 VS. 2035 VS. 2045 67
TABLE 2 GLOBAL DIABETES ESTIMATES (AGES 20–79) BY REGION,
2024 VS. 2030 VS. 2045 (IN THOUSANDS) 68
TABLE 3 PRODUCT WAIVERS, BY KEY PLAYER, 2021–2026 70
TABLE 4 POC DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 81
TABLE 5 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2024–2031 82
TABLE 6 NORTH AMERICA: MACROECONOMIC INDICATORS 83
TABLE 7 EUROPE: MACROECONOMIC INDICATORS 83
TABLE 8 ASIA PACIFIC: MACROECONOMIC INDICATORS 84
TABLE 9 LATIN AMERICA: MACROECONOMIC INDICATORS 84
TABLE 10 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 84
TABLE 11 POC DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 87
TABLE 12 AVERAGE SELLING PRICE OF POC TESTS, BY PRODUCT, 2023–2025 89
TABLE 13 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS,
BY KEY PLAYER, 2023–2025 90
TABLE 14 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS,
BY REGION, 2023–2025 90
TABLE 15 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS,
BY REGION, 2023–2025 91
TABLE 16 AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS,
BY REGION, 2023–2025 92
TABLE 17 US-ADJUSTED RECIPROCAL TARIFF RATES 96
TABLE 18 LIST OF MAJOR PATENTS PERTAINING TO POC DIAGNOSTICS MARKET, 2023–2025 102
TABLE 19 KEY COMPANIES IMPLEMENTING AI IN POC DIAGNOSTICS MARKET 105
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 107
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 107
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 108
TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 109
TABLE 24 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 109
TABLE 25 GLOBAL STANDARDS IN POC DIAGNOSTICS MARKET 110
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%) 114
TABLE 27 KEY BUYING CRITERIA, BY TECHNOLOGY 114
TABLE 28 ADOPTION BARRIERS & INTERNAL CHALLENGES 115
TABLE 29 POC DIAGNOSTICS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 116
TABLE 30 POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 120
TABLE 31 KEY BIOCHEMISTRY-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 121
TABLE 32 POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY REGION,
2024–2031 (USD MILLION) 122
TABLE 33 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY,
BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 34 EUROPE: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY,
BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 35 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY,
BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 36 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY,
BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 37 KEY IMMUNOASSAY-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 124
TABLE 38 POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION,
2024–2031 (USD MILLION) 125
TABLE 39 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 40 EUROPE: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 41 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 42 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 43 POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 128
TABLE 44 POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY REGION, 2024–2031 (USD MILLION) 128
TABLE 45 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 46 EUROPE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 47 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 48 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 49 KEY RT-PCR-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 130
TABLE 50 POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION,
2024–2031 (USD MILLION) 131
TABLE 51 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR,
BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 52 EUROPE: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR,
BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 53 ASIA PACIFIC: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR,
BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 54 LATIN AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR,
BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 55 KEY INAAT-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 133
TABLE 56 POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION,
2024–2031 (USD MILLION) 133
TABLE 57 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT,
BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 58 EUROPE: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT,
BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 59 ASIA PACIFIC: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT,
BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 60 LATIN AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT,
BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 61 POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 136
TABLE 62 KEY BLOOD SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 137
TABLE 63 POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION,
2024–2031 (USD MILLION) 138
TABLE 64 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES,
BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 65 EUROPE: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES,
BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 66 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES,
BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 67 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES,
BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 68 KEY NASAL AND OROPHARYNGEAL SWAB-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 141
TABLE 69 POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS,
BY REGION, 2024–2031 (USD MILLION) 141
TABLE 70 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 71 EUROPE: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS,
BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 72 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 73 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 74 KEY URINE SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 144
TABLE 75 POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION,
2024–2031 (USD MILLION) 144
TABLE 76 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR URINE SAMPLES,
BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 77 EUROPE: POC DIAGNOSTICS MARKET FOR URINE SAMPLES,
BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 78 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR URINE SAMPLES,
BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 79 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR URINE SAMPLES,
BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 80 KEY OTHER SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE 147
TABLE 81 POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION,
2024–2031 (USD MILLION) 147
TABLE 82 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES,
BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 83 EUROPE: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES,
BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 84 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES,
BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 85 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES,
BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 86 POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 151
TABLE 87 KEY PRESCRIPTION-BASED TESTING PRODUCTS AVAILABLE WORLDWIDE 152
TABLE 88 POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS,
BY REGION, 2024–2031 (USD MILLION) 153
TABLE 89 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 90 EUROPE: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 91 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 92 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 93 KEY OTC TESTING PRODUCTS AVAILABLE WORLDWIDE 156
TABLE 94 POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS,
BY REGION, 2024–2031 (USD MILLION) 156
TABLE 95 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS,
BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 96 EUROPE: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS,
BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 97 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS,
BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 98 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS,
BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 99 POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 160
TABLE 100 POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY REGION, 2024–2031 (USD MILLION) 161
TABLE 101 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 102 EUROPE: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 103 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 104 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 105 POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING,
BY REGION, 2024–2031 (USD MILLION) 164
TABLE 106 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS
& SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 107 EUROPE: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS
& SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 108 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS &
SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 109 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS &
SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 110 POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS,
AND URGENT CARE CENTERS, BY REGION, 2024–2031 (USD MILLION) 167
TABLE 111 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR HOSPITALS,
CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY,
2024–2031 (USD MILLION) 167
TABLE 112 EUROPE: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 113 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR HOSPITALS,
CRITICAL CARE CENTERS, AND URGENT CARE CENTERS,
BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 114 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR HOSPITALS,
CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, B
Y COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 115 POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY REGION, 2024–2031 (USD MILLION) 169
TABLE 116 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 117 EUROPE: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 118 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 119 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 120 POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION,
2024–2031 (USD MILLION) 172
TABLE 121 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 122 EUROPE: POC DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 123 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 124 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 125 POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 175
TABLE 126 POC GLUCOSE MONITORING PRODUCTS MARKET, BY REGION,
2024–2031 (USD MILLION) 176
TABLE 127 POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 177
TABLE 128 NORTH AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 129 EUROPE: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 130 ASIA PACIFIC: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 131 LATIN AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 132 KEY GLUCOSE MONITORING STRIPS AVAILABLE WORLDWIDE 179
TABLE 133 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2024–2031 (USD MILLION) 179
TABLE 134 NORTH AMERICA: GLUCOSE MONITORING STRIPS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 135 EUROPE: GLUCOSE MONITORING STRIPS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 136 ASIA PACIFIC: GLUCOSE MONITORING STRIPS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 137 LATIN AMERICA: GLUCOSE MONITORING STRIPS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 138 KEY GLUCOSE MONITORING METERS AVAILABLE WORLDWIDE 181
TABLE 139 GLUCOSE MONITORING METERS MARKET, BY REGION,
2024–2031 (USD MILLION) 182
TABLE 140 NORTH AMERICA: GLUCOSE MONITORING METERS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 141 EUROPE: GLUCOSE MONITORING METERS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 142 ASIA PACIFIC: GLUCOSE MONITORING METERS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 143 LATIN AMERICA: GLUCOSE MONITORING METERS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 144 KEY GLUCOSE MONITORING LANCETS & LANCING DEVICES AVAILABLE WORLDWIDE 184
TABLE 145 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET,
BY REGION, 2024–2031 (USD MILLION) 185
TABLE 146 NORTH AMERICA: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 147 EUROPE: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 148 ASIA PACIFIC: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 149 LATIN AMERICA: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 150 KEY CARDIOMETABOLIC TESTING PRODUCTS AVAILABLE WORLDWIDE 187
TABLE 151 POC CARDIOMETABOLIC TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 188
TABLE 152 POC CARDIOMETABOLIC TESTING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 188
TABLE 153 NORTH AMERICA: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 154 EUROPE: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 155 ASIA PACIFIC: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 156 LATIN AMERICA: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 157 CARDIAC MARKER TESTING PRODUCTS MARKET, BY REGION,
2024–2031 (USD MILLION) 191
TABLE 158 NORTH AMERICA: CARDIAC MARKER TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 159 EUROPE: CARDIAC MARKER TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 160 ASIA PACIFIC: CARDIAC MARKER TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 161 LATIN AMERICA: CARDIAC MARKER TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 162 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 193
TABLE 163 NORTH AMERICA: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 164 EUROPE: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET,
BY REGION, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 165 ASIA PACIFIC: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 166 LATIN AMERICA: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 167 HBA1C TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 196
TABLE 168 NORTH AMERICA: HBA1C TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 169 EUROPE: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 196
TABLE 170 ASIA PACIFIC: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 171 LATIN AMERICA: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 172 POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 198
TABLE 173 POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY REGION,
2024–2031 (USD MILLION) 199
TABLE 174 NORTH AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 175 EUROPE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 176 ASIA PACIFIC: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 177 LATIN AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 178 RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE,
2024–2031 (USD MILLION) 201
TABLE 179 RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION,
2024–2031 (USD MILLION) 201
TABLE 180 NORTH AMERICA: RESPIRATORY INFECTION TESTING PRODUCTS,
BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 181 EUROPE: RESPIRATORY INFECTION TESTING PRODUCTS,
BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 182 ASIA PACIFIC: RESPIRATORY INFECTION TESTING PRODUCTS,
BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 183 LATIN AMERICA: RESPIRATORY INFECTION TESTING PRODUCTS,
BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 184 KEY INFLUENZA TESTING PRODUCTS AVAILABLE WORLDWIDE 204
TABLE 185 INFLUENZA TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 204
TABLE 186 NORTH AMERICA: INFLUENZA TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 187 EUROPE: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 205
TABLE 188 ASIA PACIFIC: INFLUENZA TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 189 LATIN AMERICA: INFLUENZA TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 190 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE WORLDWIDE 206
TABLE 191 TUBERCULOSIS TESTING PRODUCTS MARKET, BY REGION,
2024–2031 (USD MILLION) 207
TABLE 192 NORTH AMERICA: TUBERCULOSIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 193 EUROPE: TUBERCULOSIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 194 ASIA PACIFIC: TUBERCULOSIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 195 LATIN AMERICA: TUBERCULOSIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 196 OTHER KEY RESPIRATORY INFECTIONS TESTING PRODUCTS AVAILABLE WORLDWIDE 209
TABLE 197 OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 209
TABLE 198 NORTH AMERICA: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 199 EUROPE: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 200 ASIA PACIFIC: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 201 LATIN AMERICA: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 202 KEY HAI TESTING PRODUCTS AVAILABLE WORLDWIDE 212
TABLE 203 HAI TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 212
TABLE 204 NORTH AMERICA: HAI TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 205 EUROPE: HAI TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 213
TABLE 206 ASIA PACIFIC: HAI TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 213
TABLE 207 LATIN AMERICA: HAI TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 213
TABLE 208 KEY TROPICAL DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE 214
TABLE 209 TROPICAL DISEASE TESTING PRODUCTS MARKET, BY REGION,
2024–2031 (USD MILLION) 215
TABLE 210 NORTH AMERICA: TROPICAL DISEASE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 211 EUROPE: TROPICAL DISEASE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 212 ASIA PACIFIC: TROPICAL DISEASE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 213 LATIN AMERICA: TROPICAL DISEASE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 214 STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 217
TABLE 215 STD TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 217
TABLE 216 NORTH AMERICA: STD TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 217 EUROPE: STD TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 218
TABLE 218 ASIA PACIFIC: STD TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 218
TABLE 219 LATIN AMERICA: STD TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 219
TABLE 220 KEY HIV TESTING PRODUCTS AVAILABLE WORLDWIDE 219
TABLE 221 HIV TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 220
TABLE 222 NORTH AMERICA: HIV TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 223 EUROPE: HIV TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 221
TABLE 224 ASIA PACIFIC: HIV TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 225 LATIN AMERICA: HIV TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 226 HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 222
TABLE 227 HEPATITIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 223
TABLE 228 NORTH AMERICA: HEPATITIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 229 EUROPE: HEPATITIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 230 ASIA PACIFIC: HEPATITIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 231 LATIN AMERICA: HEPATITIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 232 KEY HEPATITIS B TESTING PRODUCTS AVAILABLE WORLDWIDE 225
TABLE 233 HEPATITIS B TESTING PRODUCTS MARKET, BY REGION,
2024–2031 (USD MILLION) 225
TABLE 234 NORTH AMERICA: HEPATITIS B TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 235 EUROPE: HEPATITIS B TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 236 ASIA PACIFIC: HEPATITIS B TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 237 LATIN AMERICA: HEPATITIS B TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 238 KEY HEPATITIS C TESTING PRODUCTS AVAILABLE WORLDWIDE 227
TABLE 239 HEPATITIS C TESTING PRODUCTS MARKET, BY REGION,
2024–2031 (USD MILLION) 228
TABLE 240 NORTH AMERICA: HEPATITIS C TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 241 EUROPE: HEPATITIS C TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 242 ASIA PACIFIC: HEPATITIS C TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 229
TABLE 243 LATIN AMERICA: HEPATITIS C TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 229
TABLE 244 KEY SYPHILIS TESTING PRODUCTS AVAILABLE WORLDWIDE 230
TABLE 245 SYPHILIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 230
TABLE 246 NORTH AMERICA: SYPHILIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 247 EUROPE: SYPHILIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 248 ASIA PACIFIC: SYPHILIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 249 LATIN AMERICA: SYPHILIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 250 KEY HPV TESTING PRODUCTS AVAILABLE WORLDWIDE 233
TABLE 251 HPV TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 233
TABLE 252 NORTH AMERICA: HPV TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 233
TABLE 253 EUROPE: HPV TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 234
TABLE 254 ASIA PACIFIC: HPV TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 255 LATIN AMERICA: HPV TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 256 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE WORLDWIDE 236
TABLE 257 CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 236
TABLE 258 NORTH AMERICA: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 259 EUROPE: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 260 ASIA PACIFIC: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 261 LATIN AMERICA: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 238
TABLE 262 NEISSERIA GONORRHEA TESTING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 239
TABLE 263 NORTH AMERICA: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 264 EUROPE: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 265 ASIA PACIFIC: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 240
TABLE 266 LATIN AMERICA: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 240
TABLE 267 KEY HSV TESTING PRODUCTS AVAILABLE WORLDWIDE 241
TABLE 268 HSV TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 241
TABLE 269 NORTH AMERICA: HSV TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 270 EUROPE: HSV TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 242
TABLE 271 ASIA PACIFIC: HSV TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 272 LATIN AMERICA: HSV TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 273 KEY CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
AVAILABLE WORLDWIDE 243
TABLE 274 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 243
TABLE 275 NORTH AMERICA: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 276 EUROPE: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 277 ASIA PACIFIC: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 278 LATIN AMERICA: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 245
TABLE 279 OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE 246
TABLE 280 OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 246
TABLE 281 NORTH AMERICA: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 282 EUROPE: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 247
TABLE 283 ASIA PACIFIC: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 247
TABLE 284 LATIN AMERICA: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 248
TABLE 285 POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 249
TABLE 286 POC COAGULATION MONITORING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 249
TABLE 287 NORTH AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 288 EUROPE: POC COAGULATION MONITORING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 250
TABLE 289 ASIA PACIFIC: POC COAGULATION MONITORING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 250
TABLE 290 LATIN AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 291 PT/INR TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 251
TABLE 292 NORTH AMERICA: PT/INR TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 293 EUROPE: PT/INR TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 252
TABLE 294 ASIA PACIFIC: PT/INR TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 295 LATIN AMERICA: PT/INR TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 296 ACT/APTT TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 253
TABLE 297 NORTH AMERICA: ACT/APTT TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 254
TABLE 298 EUROPE: ACT/APTT TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 254
TABLE 299 ASIA PACIFIC: ACT/APTT TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 254
TABLE 300 LATIN AMERICA: ACT/APTT TESTING PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 255
TABLE 301 POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 255
TABLE 302 POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 256
TABLE 303 NORTH AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 304 EUROPE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 305 ASIA PACIFIC: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 257
TABLE 306 LATIN AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 257
TABLE 307 KEY PREGNANCY TESTING PRODUCTS AVAILABLE WORLDWIDE 258
TABLE 308 PREGNANCY TESTING PRODUCTS MARKET, BY REGION,
2024–2031 (USD MILLION) 259
TABLE 309 NORTH AMERICA: PREGNANCY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 259
TABLE 310 EUROPE: PREGNANCY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 259
TABLE 311 ASIA PACIFIC: PREGNANCY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 260
TABLE 312 LATIN AMERICA: PREGNANCY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 260
TABLE 313 KEY FERTILITY TESTING PRODUCTS AVAILABLE WORLDWIDE 261
TABLE 314 FERTILITY TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 261
TABLE 315 NORTH AMERICA: FERTILITY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 261
TABLE 316 EUROPE: FERTILITY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 317 ASIA PACIFIC: FERTILITY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 318 LATIN AMERICA: FERTILITY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 319 TYPES OF CANCER CASES WORLDWIDE, 2024VS. 2045 264
TABLE 320 KEY TUMOR/CANCER MARKER TESTING PRODUCTS AVAILABLE WORLDWIDE 264
TABLE 321 POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 265
TABLE 322 NORTH AMERICA: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 265
TABLE 323 EUROPE: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 265
TABLE 324 ASIA PACIFIC: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 266
TABLE 325 LATIN AMERICA: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 266
TABLE 326 KEY URINALYSIS TESTING PRODUCTS AVAILABLE WORLDWIDE 267
TABLE 327 POC URINALYSIS TESTING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 268
TABLE 328 NORTH AMERICA: POC URINALYSIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 329 EUROPE: POC URINALYSIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 330 ASIA PACIFIC: POC URINALYSIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 331 LATIN AMERICA: POC URINALYSIS TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 332 KEY CHOLESTEROL TESTING PRODUCTS AVAILABLE WORLDWIDE 270
TABLE 333 POC CHOLESTEROL TESTING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 270
TABLE 334 NORTH AMERICA: POC CHOLESTEROL TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 271
TABLE 335 EUROPE: POC CHOLESTEROL TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 271
TABLE 336 ASIA PACIFIC: POC CHOLESTEROL TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 272
TABLE 337 LATIN AMERICA: POC CHOLESTEROL TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 272
TABLE 338 KEY HEMATOLOGY TESTING PRODUCTS AVAILABLE WORLDWIDE 273
TABLE 339 POC HEMATOLOGY TESTING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 273
TABLE 340 NORTH AMERICA: POC HEMATOLOGY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 274
TABLE 341 EUROPE: POC HEMATOLOGY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 274
TABLE 342 ASIA PACIFIC: POC HEMATOLOGY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 274
TABLE 343 LATIN AMERICA: POC HEMATOLOGY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 275
TABLE 344 KEY DRUGS-OF-ABUSE TESTING PRODUCTS AVAILABLE WORLDWIDE 275
TABLE 345 POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 276
TABLE 346 NORTH AMERICA: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 276
TABLE 347 EUROPE: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 277
TABLE 348 ASIA PACIFIC: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 277
TABLE 349 LATIN AMERICA: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 278
TABLE 350 KEY THYROID-STIMULATING HORMONE TESTING PRODUCTS
AVAILABLE WORLDWIDE 278
TABLE 351 POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 279
TABLE 352 NORTH AMERICA: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 279
TABLE 353 EUROPE: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 279
TABLE 354 ASIA PACIFIC: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 280
TABLE 355 LATIN AMERICA: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 280
TABLE 356 KEY FECAL OCCULT BLOOD TESTING PRODUCTS AVAILABLE WORLDWIDE 281
TABLE 357 POC FECAL OCCULT TESTING PRODUCTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 281
TABLE 358 NORTH AMERICA: POC FECAL OCCULT TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 359 EUROPE: POC FECAL OCCULT TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 360 ASIA PACIFIC: POC FECAL OCCULT TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 361 LATIN AMERICA: POC FECAL OCCULT TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 283
TABLE 362 OTHER KEY POC DIAGNOSTIC PRODUCTS AVAILABLE WORLDWIDE 284
TABLE 363 OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY REGION,
2024–2031 (USD MILLION) 284
TABLE 364 NORTH AMERICA: OTHER POC DIAGNOSTIC PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 365 EUROPE: OTHER POC DIAGNOSTIC PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 285
TABLE 366 ASIA PACIFIC: OTHER POC DIAGNOSTIC PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 285
TABLE 367 LATIN AMERICA: OTHER POC DIAGNOSTIC PRODUCTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 286
TABLE 368 POC DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 288
TABLE 369 NORTH AMERICA: MACROECONOMIC INDICATORS 289
TABLE 370 NORTH AMERICA: POC DIAGNOSTICS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 290
TABLE 371 NORTH AMERICA: POC DIAGNOSTICS MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 291
TABLE 372 NORTH AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 291
TABLE 373 NORTH AMERICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 292
TABLE 374 NORTH AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 292
TABLE 375 NORTH AMERICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 292
TABLE 376 NORTH AMERICA: POC STD TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 293
TABLE 377 NORTH AMERICA: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 293
TABLE 378 NORTH AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 293
TABLE 379 NORTH AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 294
TABLE 380 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 294
TABLE 381 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 294
TABLE 382 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 295
TABLE 383 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY SAMPLE,
2024–2031 (USD MILLION) 295
TABLE 384 NORTH AMERICA: POC DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 295
TABLE 385 US: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 297
TABLE 386 US: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 297
TABLE 387 US: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 298
TABLE 388 US: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 298
TABLE 389 US: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 299
TABLE 390 US: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 299
TABLE 391 US: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 300
TABLE 392 US: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 300
TABLE 393 US: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 300
TABLE 394 US: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 301
TABLE 395 US: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 301
TABLE 396 US: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 301
TABLE 397 US: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 302
TABLE 398 US: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 302
TABLE 399 CANADA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 303
TABLE 400 CANADA: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 304
TABLE 401 CANADA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 304
TABLE 402 CANADA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 304
TABLE 403 CANADA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 305
TABLE 404 CANADA: POC STD TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 305
TABLE 405 CANADA: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 305
TABLE 406 CANADA: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 306
TABLE 407 CANADA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 306
TABLE 408 CANADA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 306
TABLE 409 CANADA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 307
TABLE 410 CANADA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 307
TABLE 411 CANADA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 307
TABLE 412 CANADA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 308
TABLE 413 EUROPE: MACROECONOMIC INDICATORS 310
TABLE 414 EUROPE: POC DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 310
TABLE 415 EUROPE: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 311
TABLE 416 EUROPE: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 311
TABLE 417 EUROPE: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 312
TABLE 418 EUROPE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 312
TABLE 419 EUROPE: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 312
TABLE 420 EUROPE: POC STD TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 313
TABLE 421 EUROPE: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 313
TABLE 422 EUROPE: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 313
TABLE 423 EUROPE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 314
TABLE 424 EUROPE: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 314
TABLE 425 EUROPE: POC DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 314
TABLE 426 EUROPE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 315
TABLE 427 EUROPE: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 315
TABLE 428 EUROPE: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 315
TABLE 429 GERMANY: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 317
TABLE 430 GERMANY: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 318
TABLE 431 GERMANY: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 318
TABLE 432 GERMANY: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 318
TABLE 433 GERMANY: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 319
TABLE 434 GERMANY: POC STD TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 319
TABLE 435 GERMANY: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 319
TABLE 436 GERMANY: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 320
TABLE 437 GERMANY: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 320
TABLE 438 GERMANY: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 320
TABLE 439 GERMANY: POC DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 321
TABLE 440 GERMANY: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 321
TABLE 441 GERMANY: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 321
TABLE 442 GERMANY: POC DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 322
TABLE 443 FRANCE: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 323
TABLE 444 FRANCE: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 323
TABLE 445 FRANCE: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 324
TABLE 446 FRANCE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 324
TABLE 447 FRANCE: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 324
TABLE 448 FRANCE: POC STD TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 325
TABLE 449 FRANCE: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 325
TABLE 450 FRANCE: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 325
TABLE 451 FRANCE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 326
TABLE 452 FRANCE: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 326
TABLE 453 FRANCE: POC DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 326
TABLE 454 FRANCE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 327
TABLE 455 FRANCE: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 327
TABLE 456 FRANCE: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 327
TABLE 457 UK: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 329
TABLE 458 UK: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 329
TABLE 459 UK: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 460 UK: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 461 UK: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 462 UK: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 331
TABLE 463 UK: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 331
TABLE 464 UK: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 331
TABLE 465 UK: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 332
TABLE 466 UK: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 332
TABLE 467 UK: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 332
TABLE 468 UK: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 333
TABLE 469 UK: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 333
TABLE 470 UK: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 333
TABLE 471 ITALY: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 335
TABLE 472 ITALY: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 335
TABLE 473 ITALY: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 336
TABLE 474 ITALY: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 336
TABLE 475 ITALY: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 336
TABLE 476 ITALY: POC STD TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 337
TABLE 477 ITALY: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 337
TABLE 478 ITALY: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 337
TABLE 479 ITALY: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 338
TABLE 480 ITALY: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 338
TABLE 481 ITALY: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 338
TABLE 482 ITALY: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 339
TABLE 483 ITALY: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 339
TABLE 484 ITALY: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 339
TABLE 485 SPAIN: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 341
TABLE 486 SPAIN: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 341
TABLE 487 SPAIN: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 342
TABLE 488 SPAIN: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 342
TABLE 489 SPAIN: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 342
TABLE 490 SPAIN: POC STD TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 343
TABLE 491 SPAIN: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 343
TABLE 492 SPAIN: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 343
TABLE 493 SPAIN: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 344
TABLE 494 SPAIN: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 344
TABLE 495 SPAIN: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 344
TABLE 496 SPAIN: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 345
TABLE 497 SPAIN: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 345
TABLE 498 SPAIN: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 345
TABLE 499 REST OF EUROPE: POC DIAGNOSTICS MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 347
TABLE 500 REST OF EUROPE: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 347
TABLE 501 REST OF EUROPE: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 348
TABLE 502 REST OF EUROPE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 348
TABLE 503 REST OF EUROPE: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 348
TABLE 504 REST OF EUROPE: POC STD TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 349
TABLE 505 REST OF EUROPE: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 349
TABLE 506 REST OF EUROPE: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 349
TABLE 507 REST OF EUROPE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 350
TABLE 508 REST OF EUROPE: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 350
TABLE 509 REST OF EUROPE: POC DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 350
TABLE 510 REST OF EUROPE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 351
TABLE 511 REST OF EUROPE: POC DIAGNOSTICS MARKET, BY SAMPLE,
2024–2031 (USD MILLION) 351
TABLE 512 REST OF EUROPE: POC DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 351
TABLE 513 ASIA PACIFIC: MACROECONOMIC INDICATORS 353
TABLE 514 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 354
TABLE 515 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 354
TABLE 516 ASIA PACIFIC: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 517 ASIA PACIFIC: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 518 ASIA PACIFIC: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 519 ASIA PACIFIC: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 356
TABLE 520 ASIA PACIFIC: POC STD TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 356
TABLE 521 ASIA PACIFIC: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 356
TABLE 522 ASIA PACIFIC: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 357
TABLE 523 ASIA PACIFIC: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 357
TABLE 524 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 357
TABLE 525 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 358
TABLE 526 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 358
TABLE 527 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY SAMPLE,
2024–2031 (USD MILLION) 358
TABLE 528 ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 359
TABLE 529 CHINA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 360
TABLE 530 CHINA: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 361
TABLE 531 CHINA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 361
TABLE 532 CHINA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 361
TABLE 533 CHINA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 362
TABLE 534 CHINA: POC STD TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 362
TABLE 535 CHINA: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 362
TABLE 536 CHINA: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 363
TABLE 537 CHINA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 363
TABLE 538 CHINA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 363
TABLE 539 CHINA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 364
TABLE 540 CHINA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 364
TABLE 541 CHINA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 364
TABLE 542 CHINA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 365
TABLE 543 JAPAN: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 366
TABLE 544 JAPAN: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 367
TABLE 545 JAPAN: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 367
TABLE 546 JAPAN: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 367
TABLE 547 JAPAN: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 368
TABLE 548 JAPAN: POC STD TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 368
TABLE 549 JAPAN: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 368
TABLE 550 JAPAN: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 369
TABLE 551 JAPAN: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 369
TABLE 552 JAPAN: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 369
TABLE 553 JAPAN: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 370
TABLE 554 JAPAN: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 370
TABLE 555 JAPAN: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 370
TABLE 556 JAPAN: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 371
TABLE 557 INDIA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 373
TABLE 558 INDIA: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 373
TABLE 559 INDIA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 374
TABLE 560 INDIA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 374
TABLE 561 INDIA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 374
TABLE 562 INDIA: POC STD TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 375
TABLE 563 INDIA: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 375
TABLE 564 INDIA: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 375
TABLE 565 INDIA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 376
TABLE 566 INDIA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 376
TABLE 567 INDIA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 376
TABLE 568 INDIA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 377
TABLE 569 INDIA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 377
TABLE 570 INDIA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 377
TABLE 571 AUSTRALIA: POC DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 379
TABLE 572 AUSTRALIA: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 379
TABLE 573 AUSTRALIA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 380
TABLE 574 AUSTRALIA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 380
TABLE 575 AUSTRALIA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 380
TABLE 576 AUSTRALIA: POC STD TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 381
TABLE 577 AUSTRALIA: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 381
TABLE 578 AUSTRALIA: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 381
TABLE 579 AUSTRALIA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 382
TABLE 580 AUSTRALIA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 382
TABLE 581 AUSTRALIA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 382
TABLE 582 AUSTRALIA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 383
TABLE 583 AUSTRALIA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 383
TABLE 584 AUSTRALIA: POC DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 383
TABLE 585 SOUTH KOREA: POC DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 385
TABLE 586 SOUTH KOREA: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 385
TABLE 587 SOUTH KOREA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 386
TABLE 588 SOUTH KOREA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 386
TABLE 589 SOUTH KOREA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 386
TABLE 590 SOUTH KOREA: POC STD TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 387
TABLE 591 SOUTH KOREA: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 387
TABLE 592 SOUTH KOREA: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 387
TABLE 593 SOUTH KOREA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 388
TABLE 594 SOUTH KOREA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 388
TABLE 595 SOUTH KOREA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 388
TABLE 596 SOUTH KOREA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 389
TABLE 597 SOUTH KOREA: POC DIAGNOSTICS MARKET, BY SAMPLE,
2024–2031 (USD MILLION) 389
TABLE 598 SOUTH KOREA: POC DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 389
TABLE 599 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 390
TABLE 600 REST OF ASIA PACIFIC: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 391
TABLE 601 REST OF ASIA PACIFIC: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 391
TABLE 602 REST OF ASIA PACIFIC: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 391
TABLE 603 REST OF ASIA PACIFIC: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 392
TABLE 604 REST OF ASIA PACIFIC: POC STD TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 392
TABLE 605 REST OF ASIA PACIFIC: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 392
TABLE 606 REST OF ASIA PACIFIC: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 393
TABLE 607 REST OF ASIA PACIFIC: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 393
TABLE 608 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET,
BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 393
TABLE 609 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 394
TABLE 610 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 394
TABLE 611 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET,
BY SAMPLE, 2024–2031 (USD MILLION) 394
TABLE 612 REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET,
BY END USER, 2024–2031 (USD MILLION) 395
TABLE 613 LATIN AMERICA: MACROECONOMIC INDICATORS 396
TABLE 614 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 397
TABLE 615 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 397
TABLE 616 LATIN AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 398
TABLE 617 LATIN AMERICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 398
TABLE 618 LATIN AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 398
TABLE 619 LATIN AMERICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 399
TABLE 620 LATIN AMERICA: POC STD TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 399
TABLE 621 LATIN AMERICA: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 399
TABLE 622 LATIN AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 400
TABLE 623 LATIN AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 400
TABLE 624 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 400
TABLE 625 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 401
TABLE 626 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 401
TABLE 627 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY SAMPLE,
2024–2031 (USD MILLION) 401
TABLE 628 LATIN AMERICA: POC DIAGNOSTICS MARKET, BY END USER,
2024–2031 (USD MILLION) 402
TABLE 629 BRAZIL: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 403
TABLE 630 BRAZIL: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 403
TABLE 631 BRAZIL: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 404
TABLE 632 BRAZIL: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 404
TABLE 633 BRAZIL: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 404
TABLE 634 BRAZIL: POC STD TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 405
TABLE 635 BRAZIL: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 405
TABLE 636 BRAZIL: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 405
TABLE 637 BRAZIL: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 406
TABLE 638 BRAZIL: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 406
TABLE 639 BRAZIL: POC DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 406
TABLE 640 BRAZIL: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 407
TABLE 641 BRAZIL: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 407
TABLE 642 BRAZIL: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 407
TABLE 643 MEXICO: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 409
TABLE 644 MEXICO: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 409
TABLE 645 MEXICO: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 646 MEXICO: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 647 MEXICO: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 648 MEXICO: POC STD TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 411
TABLE 649 MEXICO: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 411
TABLE 650 MEXICO: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 411
TABLE 651 MEXICO: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 412
TABLE 652 MEXICO: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2024–2031 (USD MILLION) 412
TABLE 653 MEXICO: POC DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 412
TABLE 654 MEXICO: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 413
TABLE 655 MEXICO: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION) 413
TABLE 656 MEXICO: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 413
TABLE 657 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 415
TABLE 658 REST OF LATIN AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 415
TABLE 659 REST OF LATIN AMERICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 416
TABLE 660 REST OF LATIN AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 416
TABLE 661 REST OF LATIN AMERICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 416
TABLE 662 REST OF LATIN AMERICA: POC STD TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 417
TABLE 663 REST OF LATIN AMERICA: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 417
TABLE 664 REST OF LATIN AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 417
TABLE 665 REST OF LATIN AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 418
TABLE 666 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET,
BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 418
TABLE 667 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 418
TABLE 668 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 419
TABLE 669 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET,
BY SAMPLE, 2024–2031 (USD MILLION) 419
TABLE 670 REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET,
BY END USER, 2024–2031 (USD MILLION) 419
TABLE 671 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 421
TABLE 672 MIDDLE EAST & AFRICA: POC GLUCOSE MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 421
TABLE 673 MIDDLE EAST & AFRICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 422
TABLE 674 MIDDLE EAST & AFRICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 422
TABLE 675 MIDDLE EAST & AFRICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 422
TABLE 676 MIDDLE EAST & AFRICA: POC STD TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 423
TABLE 677 MIDDLE EAST & AFRICA: POC HEPATITIS TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 423
TABLE 678 MIDDLE EAST & AFRICA: POC COAGULATION MONITORING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 423
TABLE 679 MIDDLE EAST & AFRICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 424
TABLE 680 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET,
BY MODE OF PURCHASE, 2024–2031 (USD MILLION) 424
TABLE 681 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 424
TABLE 682 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 425
TABLE 683 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET,
BY SAMPLE, 2024–2031 (USD MILLION) 425
TABLE 684 MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET,
BY END USER, 2024–2031 (USD MILLION) 425
TABLE 685 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES,
JANUARY 2023–JUNE 2026 426
TABLE 686 POC DIAGNOSTICS MARKET: DEGREE OF COMPETITION 430
TABLE 687 POC DIAGNOSTICS MARKET: REGION FOOTPRINT 436
TABLE 688 POC DIAGNOSTICS MARKET: MODE OF PURCHASE FOOTPRINT 437
TABLE 689 POC DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT 438
TABLE 690 POC DIAGNOSTICS MARKET: SAMPLE FOOTPRINT 439
TABLE 691 POC DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 442
TABLE 692 POC DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING
OF STARTUPS/SMES (1/2) 443
TABLE 693 POC DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING
OF STARTUPS/SMES (2/2) 443
TABLE 694 POC DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–JUNE 2026 444
TABLE 695 ABBOTT: COMPANY OVERVIEW 445
TABLE 696 ABBOTT: PRODUCTS OFFERED 446
TABLE 697 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 449
TABLE 698 ABBOTT: DEALS, JANUARY 2023–JUNE 2026 449
TABLE 699 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 451
TABLE 700 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 452
TABLE 701 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2023–JUNE 2026 454
TABLE 702 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2023–JUNE 2026 455
TABLE 703 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2023–JUNE 2026 455
TABLE 704 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 457
TABLE 705 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 458
TABLE 706 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2023–JUNE 2026 460
TABLE 707 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2023–JUNE 2026 460
TABLE 708 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2023–JUNE 2026 461
TABLE 709 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 463
TABLE 710 QUIDELORTHO CORPORATION: PRODUCTS OFFERED 464
TABLE 711 QUIDELORTHO CORPORATION: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2023–JUNE 2026 466
TABLE 712 QUIDELORTHO CORPORATION: DEALS, JANUARY 2023–JUNE 2026 467
TABLE 713 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2023–JUNE 2026 467
TABLE 714 DANAHER: COMPANY OVERVIEW 469
TABLE 715 DANAHER: PRODUCTS OFFERED 470
TABLE 716 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 472
TABLE 717 DANAHER: DEALS, JANUARY 2023–JUNE 2026 472
TABLE 718 DANAHER: EXPANSIONS, JANUARY 2023–JUNE 2026 473
TABLE 719 WERFEN: COMPANY OVERVIEW 474
TABLE 720 WERFEN: PRODUCTS OFFERED 475
TABLE 721 WERFEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 476
TABLE 722 WERFEN: DEALS, JANUARY 2023–JUNE 2026 476
TABLE 723 WERFEN: EXPANSIONS, JANUARY 2023–JUNE 2026 477
TABLE 724 BD: COMPANY OVERVIEW 478
TABLE 725 BD: PRODUCTS OFFERED 479
TABLE 726 BD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 480
TABLE 727 BD: DEALS, JANUARY 2023–JUNE 2026 480
TABLE 728 BD: EXPANSIONS, JANUARY 2023–JUNE 2026 481
TABLE 729 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 482
TABLE 730 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 484
TABLE 731 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–JUNE 2026 484
TABLE 732 BIOMÉRIEUX: COMPANY OVERVIEW 485
TABLE 733 BIOMÉRIEUX: PRODUCTS OFFERED 486
TABLE 734 BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 487
TABLE 735 BIOMÉRIEUX: DEALS, JANUARY 2023–JUNE 2026 488
TABLE 736 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW 489
TABLE 737 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED 490
TABLE 738 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 491
TABLE 739 EKF DIAGNOSTICS HOLDINGS PLC: EXPANSIONS, JANUARY 2023–JUNE 2026 491
TABLE 740 EKF DIAGNOSTICS HOLDINGS PLC: OTHER DEVELOPMENTS,
JANUARY 2023–JUNE 2026 492
TABLE 741 TRINITY BIOTECH: COMPANY OVERVIEW 493
TABLE 742 TRINITY BIOTECH: PRODUCTS OFFERED 494
TABLE 743 TRINITY BIOTECH: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2023–JUNE 2026 495
TABLE 744 TRINITY BIOTECH: DEALS, JANUARY 2023–JUNE 2026 495
TABLE 745 ORASURE TECHNOLOGIES, INC.: COMPANY OVERVIEW 496
TABLE 746 ORASURE TECHNOLOGIES, INC.: PRODUCTS OFFERED 497
TABLE 747 ORASURE TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2023–JUNE 2026 498
TABLE 748 ORASURE TECHNOLOGIES, INC.: DEALS, JANUARY 2023–JUNE 2026 499
TABLE 749 GRIFOLS S.A.: COMPANY OVERVIEW 500
TABLE 750 GRIFOLS S.A.: PRODUCTS OFFERED 501
TABLE 751 GRIFOLS S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 502
TABLE 752 QIAGEN: COMPANY OVERVIEW 503
TABLE 753 QIAGEN: PRODUCTS OFFERED 504
TABLE 754 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026 505
TABLE 755 QIAGEN: DEALS, JANUARY 2023–JUNE 2026 506
TABLE 756 QIAGEN: EXPANSIONS, JANUARY 2023–JUNE 2026 506
TABLE 757 NOVA BIOMEDICAL: COMPANY OVERVIEW 507
TABLE 758 NOVA BIOMEDICAL: PRODUCTS OFFERED 507
TABLE 759 NOVA BIOMEDICAL: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2023–JUNE 2026 508
TABLE 760 NOVA BIOMEDICAL: DEALS, JANUARY 2023–JUNE 2026 509
TABLE 761 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW 510
TABLE 762 SEKISUI DIAGNOSTICS: PRODUCTS OFFERED 510
TABLE 763 SEKISUI DIAGNOSTICS: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2023–JUNE 2026 511
TABLE 764 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW 512
TABLE 765 SEKISUI DIAGNOSTICS: PRODUCTS OFFERED 512
TABLE 766 SEKISUI DIAGNOSTICS: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2023–JUNE 2026 513
TABLE 767 LIFESCAN IP HOLDINGS, LLC: COMPANY OVERVIEW 514
TABLE 768 PTS DIAGNOSTICS: COMPANY OVERVIEW 515
TABLE 769 EUROLYSER DIAGNOSTICA GMBH: COMPANY OVERVIEW 516
TABLE 770 RESPONSE BIOMEDICAL: COMPANY OVERVIEW 517
TABLE 771 ALFA SCIENTIFIC DESIGNS, INC.: COMPANY OVERVIEW 518
TABLE 772 BTNX INC.: COMPANY OVERVIEW 519
TABLE 773 ASCENSIA DIABETES CARE HOLDINGS AG: COMPANY OVERVIEW 520
TABLE 774 FLUXERGY: COMPANY OVERVIEW 521
TABLE 775 PRECISION BIOSENSOR, INC.: COMPANY OVERVIEW 522
TABLE 776 ACON LABORATORIES, INC.: COMPANY OVERVIEW 523
TABLE 777 MENARINI DIAGNOSTICS S.R.L: COMPANY OVERVIEW 524
TABLE 778 MANKIND PHARMA: COMPANY OVERVIEW 525
TABLE 779 POC DIAGNOSTICS MARKET: RISK ASSESSMENT 538

LIST OF FIGURES

FIGURE 1 POC DIAGNOSTICS MARKET SEGMENTATION 49
FIGURE 2 KEY INSIGHTS AND MARKET HIGHLIGHTS 54
FIGURE 3 GLOBAL POC DIAGNOSTICS MARKET, 2024–2031 55
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN POC DIAGNOSTICS
MARKET, 2023–2025 55
FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF POC DIAGNOSTICS MARKET 56
FIGURE 6 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN POC DIAGNOSTICS MARKET, 2026-2031 57
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 58
FIGURE 8 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET 60
FIGURE 9 GLUCOSE MONITORING PRODUCTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 61
FIGURE 10 PRESCRIPTION-BASED TESTING PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD 61
FIGURE 11 BIOCHEMISTRY SEGMENT TO WITNESS LARGEST MARKET SHARE DURING FORECAST PERIOD 62
FIGURE 12 BLOOD SAMPLES SEGMENT TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD 62
FIGURE 13 HOME CARE SETTINGS & SELF-TESTING SEGMENT TO HOLD LARGEST
MARKET SHARE 63
FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 63
FIGURE 15 POC DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 64
FIGURE 16 REGIONAL INCIDENCE OF HIV, 2025 66
FIGURE 17 POC DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 80
FIGURE 18 POC DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 85
FIGURE 19 POC DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 86
FIGURE 20 INVESTMENT AND FUNDING SCENARIO, 2021–2024 88
FIGURE 21 POC DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 93
FIGURE 22 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES IN POC DIAGNOSTICS MARKET 95
FIGURE 23 PATENT ANALYSIS FOR POC DIAGNOSTICS 101
FIGURE 24 MARKET POTENTIAL OF AI IN POC DIAGNOSTICS MARKET 104
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY 113
FIGURE 26 KEY BUYING CRITERIA, BY TECHNOLOGY 114
FIGURE 27 NORTH AMERICA: POC DIAGNOSTICS MARKET SNAPSHOT 290
FIGURE 28 ASIA PACIFIC: POC DIAGNOSTICS MARKET SNAPSHOT 353
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN POC DIAGNOSTICS MARKET 2023–2025 429
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 429
FIGURE 31 EV/EBITDA OF KEY VENDORS, 2024 431
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS, 2024 431
FIGURE 33 POC DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON 432
FIGURE 34 POC DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 434
FIGURE 35 POC DIAGNOSTICS MARKET: COMPANY FOOTPRINT 435
FIGURE 36 POC DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2025 441
FIGURE 37 ABBOTT: COMPANY SNAPSHOT (2025) 446
FIGURE 38 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 452
FIGURE 39 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025) 458
FIGURE 40 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2025) 464
FIGURE 41 DANAHER: COMPANY SNAPSHOT (2025) 470
FIGURE 42 WERFEN: COMPANY SNAPSHOT (2025) 475
FIGURE 43 BD: COMPANY SNAPSHOT (2025) 479
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 483
FIGURE 45 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 486
FIGURE 46 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2025) 490
FIGURE 47 TRINITY BIOTECH: COMPANY SNAPSHOT (2025) 494
FIGURE 48 ORASURE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 497
FIGURE 49 GRIFOLS S.A.: COMPANY SNAPSHOT (2025) 501
FIGURE 50 QIAGEN: COMPANY SNAPSHOT (2025) 504
FIGURE 51 POC DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY 526
FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 531
FIGURE 53 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 532
FIGURE 54 GLOBAL POC DIAGNOSTICS MARKET: REVENUE SHARE ANALYSIS 533
FIGURE 55 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 534
FIGURE 56 TOP-DOWN APPROACH 535
FIGURE 57 DATA TRIANGULATION METHODOLOGY 536

---

---